• 6020 Citations
  • 33 h-Index
1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 6020 Citations
  • 33 h-Index
  • 118 Article
  • 6 Review article
  • 5 Letter
  • 1 Comment/debate
Filter
Article
2020

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Sureda, A., Chabannon, C., Masszi, T., Pohlreich, D., Scheid, C., Thieblemont, C., Wahlin, B. E., Sakellari, I., Russell, N., Janikova, A., Dabrowska-Iwanicka, A., Touzeau, C., Esquirol, A., Jantunen, E., van der Werf, S., Bosman, P., Boumendil, A., Liu, Q., Celanovic, M., Montoto, S. & 1 others, Dreger, P., Mar 1 2020, In : Bone Marrow Transplantation. 55, 3, p. 613-622 10 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Identification of the best-suited donor for generating virus-specific T cells

Tasnády, S., Karászi, É., Szederjesi, A., Bihari, G., Juhász, Z., Hardi, A., Kriván, G., Kállay, K., Reményi, P., Sinkó, J., Mikala, G., Réti, M. & Masszi, T., Jan 1 2020, In : Vox sanguinis. 115, 1, p. 18-26 9 p.

Research output: Contribution to journalArticle

Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation

Kövy, P., Meggyesi, N., Varga, L., Balassa, K., Bors, A., Gopcsa, L., Paksi, M., Bátai, Á., Vad, E., Sinkó, J., Tordai, A., Masszi, T., Reményi, P. & Andrikovics, H., Jan 1 2020, In : Bone Marrow Transplantation. 55, 1, p. 215-223 9 p.

Research output: Contribution to journalArticle

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Morris, C., Chabannon, C., Masszi, T., Russell, N., Nahi, H., Kobbe, G., Krejci, M., Auner, H. W., Pohlreich, D., Hayden, P., Basak, G. W., Lenhoff, S., Schaap, N., van Biezen, A., Knol, C., Iacobelli, S., Liu, Q., Celanovic, M., Garderet, L. & Kröger, N., Feb 1 2020, In : Bone Marrow Transplantation. 55, 2, p. 356-366 11 p.

Research output: Contribution to journalArticle

Open Access
1 Citation (Scopus)
2019

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms

Mózes, R., Gángó, A., Sulák, A., Vida, L., Reiniger, L., Timár, B., Krenács, T., Alizadeh, H., Masszi, T., Gaál-Weisinger, J., Demeter, J., Csomor, J., Matolcsy, A., Kajtár, B. & Bödör, C., Apr 2019, In : Pathology. 51, 3, p. 301-307 7 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning

Tordai, A., Bors, A., Kiss, K. P., Balassa, K., Andrikovics, H., Batai, A., Szilvasi, A., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Remenyi, P. & Masszi, T., Jan 1 2019, In : PloS one. 14, 6, e0218945.

Research output: Contribution to journalArticle

Open Access
3 Citations (Scopus)

Effectiveness of intra-arterial steroid administration for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease

Bérczi, V., Tóth, A., Tatai, G., Fábián, J., Reményi, P. & Masszi, T., Jan 1 2019, (Accepted/In press) In : Clinical Radiology.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia

on behalf of the Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation, May 2019, In : British Journal of Haematology. 185, 4, p. 725-732 8 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Lovas, S., Varga, G., Farkas, P., Masszi, T., Wohner, N., Bereczki, Á., Adamkovich, N., Borbényi, Z., Szomor, Á., Alizadeh, H., Szaleczky, E., Wolf, K., Schneider, T., Plander, M., Szendrei, T., Csacsovszki, O., Csukly, Z., Rajnics, P., Egyed, M., Nagy, Z. & 4 others, Rejtő, L., Illés, Á., Mikala, G. & Váróczy, L., Nov 1 2019, In : International Journal of Hematology. 110, 5, p. 559-565 7 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)
2018

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT

Giebel, S., Labopin, M., Potter, M., Poiré, X., Sengeloev, H., Socié, G., Huynh, A., Afanasyev, B. V., Schanz, U., Ringden, O., Kalhs, P., Beelen, D. W., Campos, A. M., Masszi, T., Canaani, J., Mohty, M. & Nagler, A., Jun 1 2018, In : European Journal of Cancer. 96, p. 73-81 9 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., May 1 2018, In : Journal of cancer research and clinical oncology. 144, 5, p. 945-954 10 p.

Research output: Contribution to journalArticle

35 Citations (Scopus)

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Kiladjian, J. J., Guglielmelli, P., Griesshammer, M., Saydam, G., Masszi, T., Durrant, S., Passamonti, F., Jones, M., Zhen, H., Li, J., Gadbaw, B., Perez Ronco, J., Khan, M. & Verstovsek, S., Apr 1 2018, In : Annals of Hematology. 97, 4, p. 617-627 11 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Schneider, T., Rosta, A., Losonczy, H., Radványi, G., Ujj, G., Egyed, M., Illés, Á., Jakucs, J., Szerafin, L., Gasztonyi, Z., Masszi, T., Iványi, J., Demeter, J., Dombi, P., Tóth, A. & Borbényi, Z., Apr 1 2018, In : Pathology and Oncology Research. 24, 2, p. 199-205 7 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Viviani, S., Bachanova, V., Sureda, A., McClendon, T., Lee, C., Lisano, J. & Sweetenham, J., Dec 20 2018, In : Blood. 132, 25, p. 2639-2642 4 p.

Research output: Contribution to journalArticle

25 Citations (Scopus)

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party

Akhtar, S., Montoto, S., Boumendil, A., Finel, H., Masszi, T., Jindra, P., Nemet, D., Fuhrmann, S., Beguin, Y., Castagna, L., Ferrara, F., Capria, S., Malladi, R., Moraleda, J. M., Bloor, A., Ghesquières, H., Meissner, J., Sureda, A. & Dreger, P., Jan 1 2018, In : American Journal of Hematology. 93, 1, p. 40-46 7 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT

Gagelmann, N., Eikema, D. J., Iacobelli, S., Koster, L., Nahi, H., Stoppa, A. M., Masszi, T., Caillot, D., Lenhoff, S., Udvardy, M., Crawley, C., Arcese, W., Mariette, C., Hunter, A., Leleu, X., Schipperus, M., Delforge, M., Pioltelli, P., Snowden, J. A., Itälä-Remes, M. & 4 others, Musso, M., van Biezen, A., Garderet, L. & Kröger, N., Apr 30 2018, In : Haematologica. 103, 5, p. 890-897 8 p.

Research output: Contribution to journalArticle

11 Citations (Scopus)

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Leleu, X., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O., Rosiñol, L., Langer, C., Song, K., Izumi, T., Cleeland, C., Berg, D., Lin, H. M., Zhu, Y., Skacel, T., Moreau, P. & Richardson, P. G., Aug 2018, In : American Journal of Hematology. 93, 8, p. 985-993 9 p.

Research output: Contribution to journalArticle

18 Citations (Scopus)

Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies

Balassa, K., Andrikovics, H., Remenyi, P., Batai, A., Szilvasi, A., Bors, A., Kiss, K. P., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Gopcsa, L., Tordai, A. & Masszi, T., Jan 2018, In : Human Immunology. 79, 1, p. 13-19 7 p.

Research output: Contribution to journalArticle

Skin-homing CD8 + T cells preferentially express GPI-anchored peptidase inhibitor 16, an inhibitor of cathepsin K

Lupsa, N., Érsek, B., Horváth, A., Bencsik, A., Lajkó, E., Silló, P., Oszvald, Á., Wiener, Z., Reményi, P., Mikala, G., Masszi, T., Buzás, E. I. & Pós, Z., Dec 2018, In : European journal of immunology. 48, 12, p. 1944-1957 14 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

Kiss, K. P., Varga, G., Mikala, G., Balassa, K., Bors, A., Kovy, P., Meggyesi, N., Kozma, A., Csacsovszki, O., Remenyi, P., Valyi-Nagy, I., Tordai, A., Masszi, T. & Andrikovics, H., Mar 4 2018, In : Leukemia and Lymphoma. 59, 3, p. 710-716 7 p.

Research output: Contribution to journalArticle

2017

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A., Rosiñol, L., Nagler, A., Yong, K. L., Oriol, A., Minarik, J., Pour, L., Dimopoulos, M. A., Maisnar, V., Rossi, D., Kasparu, H., Van Droogenbroeck, J., Yehuda, D. B., Hardan, I., Jenner, M., Calbecka, M., Dávid, M. & 12 others, De La Rubia, J., Drach, J., Gasztonyi, Z., Górnik, S., Leleu, X., Munder, M., Offidani, M., Zojer, N., Rajangam, K., Chang, Y. L., San-Miguel, J. F. & Ludwig, H., Jan 1 2017, In : Leukemia. 31, 1, p. 107-114 8 p.

Research output: Contribution to journalArticle

64 Citations (Scopus)

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

Dimopoulos, M. A., Stewart, A. K., Masszi, T., Spicka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Ro, S., Aggarwal, S., Moreau, P. & Palumbo, A., Jan 1 2017, In : Blood Cancer Journal. 7, 4, e554.

Research output: Contribution to journalArticle

27 Citations (Scopus)

Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Mateos, M. V., Masszi, T., Grzasko, N., Hansson, M., Sandhu, I., Pour, L., Viterbo, L., Jackson, S. R., Stoppa, A. M., Gimsing, P., Hamadani, M., Borsaru, G., Berg, D., Lin, J., Di Bacco, A., Van De Velde, H., Richardson, P. G. & Moreau, P., Sep 30 2017, In : Haematologica. 102, 10, p. 1767-1775 9 p.

Research output: Contribution to journalArticle

22 Citations (Scopus)

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Avet-Loiseau, H., Bahlis, N. J., Chng, W. J., Masszi, T., Viterbo, L., Pour, L., Ganly, P., Palumbo, A., Cavo, M., Langer, C., Pluta, A., Nagler, A., Kumar, S., Ben-Yehuda, D., Rajkumar, S. V., San-Miguel, J., Berg, D., Lin, J., Van De Velde, H., Esseltine, D. L. & 3 others, di Bacco, A., Moreau, P. & Richardson, P. G., Dec 14 2017, In : Blood. 130, 24, p. 2610-2618 9 p.

Research output: Contribution to journalArticle

36 Citations (Scopus)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

Kumar, S., Moreau, P., Hari, P., Mateos, M. V., Ludwig, H., Shustik, C., Masszi, T., Spencer, A., Hájek, R., Romeril, K., Avivi, I., Liberati, A. M., Minnema, M. C., Einsele, H., Lonial, S., Berg, D., Lin, J., Gupta, N., Esseltine, D. L. & Richardson, P. G., Aug 2017, In : British Journal of Haematology. 178, 4, p. 571-582 12 p.

Research output: Contribution to journalArticle

28 Citations (Scopus)

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma

Varga, G., Mikala, G., Kiss, K. P., Kosóczki, É., Szabó, E., Meggyesi, N., Balassa, K., Kövy, P., Tegze, B., Szombath, G., Tordai, A., Andrikovics, H., Homolya, L. & Masszi, T., Nov 2017, In : Clinical Lymphoma, Myeloma and Leukemia. 17, 11, p. 734-742 9 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)
2016

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A. & 11 others, Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S. & Chng, W. J., Jan 1 2016, In : The Lancet Oncology. 17, 1, p. 27-38 12 p.

Research output: Contribution to journalArticle

387 Citations (Scopus)

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., Špička, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V., Mihaylov, G., Maisnar, V., Mateos, M. V., Wang, M., Niesvizky, R., Oriol, A., Jakubowiak, A., Minarik, J., Palumbo, A., Bensinger, W., Kukreti, V. & 4 others, Ben-Yehuda, D., Stewart, A. K., Obreja, M. & Moreau, P., Sep 1 2016, In : Blood. 128, 9, p. 1174-1180 7 p.

Research output: Contribution to journalArticle

62 Citations (Scopus)

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

Mesa, R., Verstovsek, S., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Zhen, H., Jones, M. M., Parasuraman, S., Li, J., Côté, I., Habr, D. & Vannucchi, A. M., Aug 1 2016, In : European journal of haematology. 97, 2, p. 192-200 9 p.

Research output: Contribution to journalArticle

24 Citations (Scopus)

Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100

Krahling, T., Balassa, K., Kiss, K. P., Bors, A., Batai, A., Halm, G., Egyed, M., Fekete, S., Remenyi, P., Masszi, T., Tordai, A. & Andrikovics, H., Jan 1 2016, In : Cancer Epidemiology Biomarkers and Prevention. 25, 1, p. 98-104 7 p.

Research output: Contribution to journalArticle

15 Citations (Scopus)

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., Mark, T. M., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A. & Sonneveld, P., Aug 25 2016, In : New England Journal of Medicine. 375, 8, p. 754-766 13 p.

Research output: Contribution to journalArticle

541 Citations (Scopus)

Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years

Remenyi, P., Varga, G., Mikala, G., Reti, M., Gopcsa, L., Batai, A., Csukly, Z., Lengyel, L., Torbagyi, E., Barta, A., Fabian, J., Levai, D., Szombath, G., Andrikovics, H. & Masszi, T., Jan 1 2016, In : Transplantation Proceedings. 48, 1, p. 177-184 8 p.

Research output: Contribution to journalArticle

8 Citations (Scopus)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the European ENEST1st study

Hochhaus, A., Rosti, G., Cross, N. C. P., Steegmann, J. L., Le Coutre, P., Ossenkoppele, G., Petrov, L., Masszi, T., Hellmann, A., Griskevicius, L., Wiktor-Jedrzejczak, W., Rea, D., Coriu, D., Brümmendorf, T. H., Porkka, K., Saglio, G., Gastl, G., Müller, M. C., Schuld, P., Di Matteo, P. & 5 others, Pellegrino, A., Dezzani, L., Mahon, F. X., Baccarani, M. & Giles, F. J., Jan 1 2016, In : Leukemia. 30, 1, p. 57-64 8 p.

Research output: Contribution to journalArticle

62 Citations (Scopus)

Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma

Stewart, A. K., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Buchanan, J., Cocks, K., Yang, X., Xing, B., Zojwalla, N., Tonda, M., Moreau, P. & Palumbo, A., Nov 10 2016, In : Journal of Clinical Oncology. 34, 32, p. 3921-3930 10 p.

Research output: Contribution to journalArticle

36 Citations (Scopus)

Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

Mátrai, Z., Andrikovics, H., Szilvási, A., Bors, A., Kozma, A., Ádám, E., Halm, G., Karászi, É., Tordai, A. & Masszi, T., Oct 18 2016, (Accepted/In press) In : Pathology and Oncology Research. p. 1-7 7 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma

TOURMALINE-MM1 Study Group, Apr 28 2016, In : New England Journal of Medicine. 374, 17, p. 1621-1634 14 p.

Research output: Contribution to journalArticle

452 Citations (Scopus)

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

Ramsey, S. D., Nademanee, A., Masszi, T., Holowiecki, J., Abidi, M., Chen, A., Stiff, P., Viviani, S., Sweetenham, J. W., Radford, J., Zhu, Y., Bonthapally, V., Thomas, E., Richhariya, A., Hunder, N. N., Walewski, J. & Moskowitz, C. H., Dec 1 2016, In : British Journal of Haematology. 175, 5, p. 860-867 8 p.

Research output: Contribution to journalArticle

10 Citations (Scopus)

Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

Balassa, K., Krahling, T., Remenyi, P., Batai, A., Bors, A., Kiss, K. P., Torbagyi, E., Gopcsa, L., Lengyel, L., Barta, A., Varga, G., Tordai, A., Masszi, T. & Andrikovics, H., Jul 7 2016, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-8 8 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation

Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J. H., Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A. & 12 others, NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F. & Carreras, E., Jul 1 2016, In : Bone Marrow Transplantation. 51, 7, p. 906-912 7 p.

Research output: Contribution to journalArticle

113 Citations (Scopus)

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Verstovsek, S., Vannucchi, A. M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Kirito, K., Besses, C., Hino, M., Moiraghi, B., Miller, C. B., Cazzola, M., Rosti, V., Blau, I., Mesa, R., Jones, M. M., Zhen, H. & 4 others, Li, J., Francillard, N., Habr, D. & Kiladjian, J. J., Jan 1 2016, In : Haematologica. 101, 7, p. 821-829 9 p.

Research output: Contribution to journalArticle

74 Citations (Scopus)
2015

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Špička, I., Maiolino, A., Suvorov, A., Bladé, J., Samoylova, O., Puchalski, T. A., Reddy, M., Bandekar, R., van de Velde, H., Xie, H. & Rossi, J. F., Jan 1 2015, In : American Journal of Hematology. 90, 1, p. 42-49 8 p.

Research output: Contribution to journalArticle

74 Citations (Scopus)

Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study

O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., Bhat, G., Choi, M. R., Walewski, J., Savage, K., Foss, F., Allen, L. F. & Shustov, A., Aug 10 2015, In : Journal of Clinical Oncology. 33, 23, p. 2492-2499 8 p.

Research output: Contribution to journalArticle

184 Citations (Scopus)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Ludwig, H., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M. B., Esteves, G., Stoppa, A. M., Robinson, D., Chaturvedi, S., Ataman, O., Enny, C., Feng, H., van de Velde, H. & Viterbo, L., Nov 2015, In : British Journal of Haematology. 171, 3, p. 344-354 11 p.

Research output: Contribution to journalArticle

18 Citations (Scopus)

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., Osmanov, D., Bachanova, V., Sweetenham, J., Sureda, A., Huebner, D., Sievers, E. L., Chi, A., Larsen, E. K., Hunder, N. N. & Walewski, J., May 9 2015, In : The Lancet. 385, 9980, p. 1853-1862 10 p.

Research output: Contribution to journalArticle

342 Citations (Scopus)

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

ASPIRE Investigators, Jan 8 2015, In : New England Journal of Medicine. 372, 2, p. 142-152 11 p.

Research output: Contribution to journalArticle

653 Citations (Scopus)

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

Varga, G., Mikala, G., Andrikovics, H., Koszarska, M., Balassa, K., Ádám, E., Kozma, A., Tordai, A. & Masszi, T., Mar 1 2015, In : British Journal of Haematology. 168, 5, p. 679-688 10 p.

Research output: Contribution to journalArticle

8 Citations (Scopus)

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

Khoury, H. J., Cortes, J., Baccarani, M., Wetzler, M., Masszi, T., Digumarti, R., Craig, A., Benichou, A. C. & Akard, L., Jan 1 2015, In : Leukemia and Lymphoma. 56, 1, p. 120-127 8 p.

Research output: Contribution to journalArticle

14 Citations (Scopus)

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia

Stone, R. M., Mazzola, E., Neuberg, D., Allen, S. L., Pigneux, A., Stuart, R. K., Wetzler, M., Rizzieri, D., Erba, H. P., Damon, L., Jang, J. H., Tallman, M. S., Warzocha, K., Masszi, T., Sekeres, M. A., Egyed, M., Horst, H. A., Selleslag, D., Solomon, S. R., Venugopal, P. & 2 others, Lundberg, A. S. & Powell, B., Mar 20 2015, In : Journal of Clinical Oncology. 33, 11, p. 1252-1257 6 p.

Research output: Contribution to journalArticle

36 Citations (Scopus)

Ruxolitinib versus standard therapy for the treatment of polycythemia vera

Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., He, S., Jones, M. M., Garrett, W., Li, J., Pirron, U., Habr, D. & Verstovsek, S., Jan 1 2015, In : New England Journal of Medicine. 372, 5, p. 426-435 10 p.

Research output: Contribution to journalArticle

282 Citations (Scopus)

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

Pardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., Drummond, M. W., Jurgutis, M., Kuliczkowski, K., Gheorghita, E., Passamonti, F., Neumann, F., Patki, A., Gao, G. & Tefferi, A., Aug 1 2015, In : JAMA oncology. 1, 5, p. 643-651 9 p.

Research output: Contribution to journalArticle

112 Citations (Scopus)